SI-BONE Inc (SIBN) Stock Forecast & Price Target

SI-BONE is viewed favorably because it is delivering sustained top-line growth, with 1Q26 revenue of $52.6 million up 11% year over year, gross margin of 79.8%, and adjusted EBITDA turning positive at $2.5 million, showing improving operating leverage as revenue grows faster than operating expenses. Its outlook is strengthened by multiple near-term catalysts, including the on-track third FDA Breakthrough Device launch in 4Q26, the Smith & Nephew partnership building toward a 3Q and 4Q contribution, and potential reimbursement tailwinds from the FY27 IPPS proposal that could materially improve Granite economics. Underpinning this is a differentiated, capital-light business focused on an underpenetrated sacropelvic market, with 1,650 active physicians, 89 territory managers, and annualized rep productivity of $2.2 million supporting durable growth and a clearer path to profitability.

SI-BONE is challenged by concentrated dependence on a single orthopedic anatomical location, making adoption vulnerable to unfavorable coverage or reimbursement changes and intensifying competition. Its global growth path also faces regulatory delays, slower product launches in emerging and developed markets, and macro headwinds such as pricing pressure, weaker demand, political uncertainty, tax-law shifts, and foreign exchange volatility. Although the company is cited as having roughly double the peer average revenue growth, above-average gross margins, and an improving profitability outlook, the writer’s negative stance is reinforced by sector multiple compression and a lower ~2x EV/Sales framework versus ~1.8x for comparable SMID-cap ortho and spine names.